New3 Cost Benefit Analysis of PBS Medications

Sardar M. N. Islam and Christine Suet Yee Mak
Additional contact information
Sardar M. N. Islam: Victoria University
Christine Suet Yee Mak: Victoria University

Chapter 6 in Normative Health Economics, 2006, pp 133-165 from Palgrave Macmillan

Abstract: Abstract In this chapter, six medications are selected for hypothetical cost benefit analysis under the type of criteria listed under the Pharmaceutical Benefit Advisory Committee (PBAC) submission guidelines, the standard approach of financial cost benefit analysis and the new3 cost benefit analysis under the normative social choice approach of new3 welfare economics.

Keywords: Discount Rate; Social Cost; Adverse Drug Effect; Complementary Medicine; Improve Health Status (search for similar items in EconPapers)
Date: 2006
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-28905-5_6

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230289055

DOI: 10.1057/9780230289055_6

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().